Some called it the strongest patent they'd ever enforced. Others saw it as a top contender for invalidation from day one. Yesterday, the Federal Patent Court made its choice.

A big win for the generics industry and for affordable healthcare – and a reminder that even the most fortified patents aren’t immune to a good team, solid arguments, and a bit of persistence.

If Bayer wasn’t nervous before, they should have been when Yasmine Azzaoui walked in – the same Yasmine who had helped take down the French Rivaroxaban patent. This time, just watching was enough.

Huge thanks to everyone who made this possible.
From the BONABRY team: Konstantin Schallmoser, Carl-Alexander Dinges, Dr. Sarah Salaschek, Yasmine Azzaoui and Daniel Hoppe. And a very special thank-you to Alexander Wittkopp (Hamm & Wittkopp Patentanwälte) and Dr. Christian Hollatz (Ter Meer Steinmeister & Partner Patentanwälte mbB) – for sharing this three-year rollercoaster with us. One that had more drops than climbs – until yesterday. One that will continue.

Also grateful to Michael Best (Kraus & Lederer), Dr. Thomas Kernebeck (Kernebeck Patentanwalts GmbH), Dr. Jan Phillip Rektorschek (Taylor Wessing), Dr. Anne Halbach and Dr. Annika L. Lückemann, LL.M. (Virginia) (Bird & Bird).

And above all: thanks to all the clients, who endured this legal thriller.

More information